On Monday, June 2, Bloomberg reported that Bristol-Myers Squibb Company (NYSE:BMY) and BioNTech SE (NASDAQ:BNTX) announced a strategic licensing agreement focused on next-generation oncology therapies, with a potential transaction value of up to $11.1 billion. The deal grants Bristol-Myers rights to BNT327, a cancer immunotherapy compound that BioNTech originally licensed from China’s biotech company Biotheus in 2023, which it later acquired for around $950 million.
Under the terms, BioNTech will receive $1.5 billion upfront, followed by $2 billion in instalment payments throughout 2028. Additional milestone payments of up to $7.6 billion are tied to development, regulatory, and commercial achievements. The companies will also share R&D, manufacturing costs, and future profits equally.
A laboratory filled with modern equipment, scientists examining the latest biotechnology breakthroughs.
The agreement also includes the flexibility for either company to evaluate BNT327 in combination with their other pipeline of compounds. If we consider the long-term benefits, for Bristol-Myers, the move strengthens its ongoing efforts to bolster its pipeline as key drugs mature and competition intensifies. On the other hand, the deal supports BioNTech’s efforts to advance combination therapies for treating tumors.
The deal reflects the increasing activity in the immuno-oncology space, with companies seeking assets that can provide treatments effective for a broader range of patients. Notably, this deal follows Pfizer’s (NYSE:PFE) recent licensing of a similar immune-oncology asset from 3SBio for up to $6.1 billion, highlighting growing competitive intensity in the field.
According to Bloomberg Intelligence, the immune-oncology market is expected to exceed $60 billion annually by 2027. They explain that these next-generation immuno-oncology therapies enhance immune checkpoint inhibitors by restricting the blood and oxygen supply to tumors. According to their analysis, this field experienced a surge last year when Akeso Inc. and Summit Therapeutics announced that their drug outperformed Merck’s Keytruda in a Chinese clinical trial, signaling a significant breakthrough in cancer treatment.
Bristol-Myers Squibb is a global biopharmaceutical company that manufactures prescription pharmaceuticals and biologics across several therapeutic areas, including oncology, hematology, immunology, cardiovascular disease, and neuroscience.
While we acknowledge the potential of BMY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BMY and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None.
Hedge Fund Resource Center